A Complete Response Achieved in a Patient with Hepatic Metastasis from Sigmoid Colon Cancer by a Regimen Containing Ramucirumab: a Case Report

Excerpt

Folinic acid and irinotecan combined with infusional 5-fluorouracil (5-FU) (FOLFIRI) combined with the anti-vascular endothelial growth factor (VEGF)-A antibody bevacizumab (Bmab) is a standard treatment for patients with metastatic colorectal cancer (mCRC) [1]. Ramucirumab (Rmab) is a VEGF receptor 2 (VEGFR-2) inhibitor that prevents not only VEGF-A but also VEGF-C and VEGF-D ligands from binding to VEGFR-2, leading to the inactivation of VEGF signaling. The phase III study RAISE compared the effects of Rmab versus placebo in combination with second-line FOLFIRI in mCRC patients who experienced progression during or after first-line therapy with Bmab, oxaliplatin, and a fluoropyrimidine. The findings showed that the combination of Rmab with FOLFIRI was an effective second-line treatment for patients with mCRC [2]. However, no patients in the RAISE trial achieved a complete response (CR) by Rmab plus FOLFIRI. Furthermore, to our knowledge, no case reports have described the achievement of a CR by this regimen either. …